Company intelligence
Hemab Therapeutics
The next generation of therapeutics for bleeding and thrombotic disorders
About Hemab Therapeutics
Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood clotting disorders like Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease and other serious disorders. Learn more at hemab.com.
Verified activity
Signals from Hemab Therapeutics
3 published signals
Research & Knowledge
Hemab Therapeutics is enrolling participants in two studies designed to advance understanding and treatment of Von Willebrand disease, including VELORA Discover and VELORA Pioneer.
Reported by Hemab Therapeutics
Presence & Recognition
Hemab Therapeutics participated in National Clinical Nurse Specialist Recognition Week to thank nurses supporting the bleeding disorders community.
Reported by Hemab Therapeutics
People
Hemab Therapeutics is hiring two Student Assistants to join the IT and Digital team in Copenhagen.
Reported by Mads Bjærge